Member Info for dallo

Clarification
The 20p warrants vest when SP reaches 30p and the 30p warrants vest when SP reaches 40p.
So we need to see 30p to raise additional £650,000 via warrants and 40p to receive a further £975,000 .
So expect some action soon to get the SP back to 40p imho.

The key now is to get the warrants exercised at 20p and then at 30p
This will transform the financial position of Ethernity and will ensure it has more than sufficient resources to reach the promised land by mid/end of 2021.
I am sure Levi is aware of this and has some deals in the pipeline to announce soon to drive the SP through 20p and from there the jump to 30p will be swift.

Rivaldo
It is all about subscriptions levels and this is the number I am looking out for in the first half years results in a few weeks time.
Given Kape's high GP %, impressive subscriber retention rates and growing free cash flow it is ,for now, all about growing the subscriber level to c 3 million over the next 12 months.
The boost from home working growth hopefully will have resulted in a jump in user numbers to near 2.5 million at the half year with good guidance for the rest of the year.
Kape has the financial resources to add subscribers through bolt on acquisitions as well as organically.
The management team appear to be top class with the only issue restraining the share price being Sagi's large shareholding which is dramatically impacting on the free float and liquidity in the shares.
Still very optimistic of further rise in the share price in the short term.
DYOR and ATB

Prennie
You are right ...we await some more deals with
more meat on the bone .
I think we are close to some significant deal flow which could be transformational.
I note the case of OpenNet who were struggling until it concluded a sizeable deal in the US and was then swooped on by Amdocs .
One of our shareholders Cipio Partners had a big holding in OpenNet ( also in 5G Technology) and made 700% return after 2 years or less.
It will happen here with just a £5m market cap Ethernity can rocket if the deals start flowing.

Don't despair....the good news to be gathered from the contract albeit small is that the company is active and moving along.
What we need is further evidence of progress with more contract wins which would transform the share .
I have a gut feeling Levi will announce more deals in the coming weeks to lock in the warrants.
DYOR and ATB

Another sneaky late buy reported..150,000 at 16.1p
Not me for a change.

The spread from bid to offer is 18% which is outrageous but why I am not surprised.

The opportunity for Ethernity is clear with a recent forecast from Ericsson that there will be over 190 million 5G subscriptions globally by the end of 2020 growing to nearly 3 billion by the end of 2025.
The economic opportunity associated with 5G and, wait for it, the next generation of networks is well documented with the global impact in goods and services expected to reach $12 trillion by 2035
( source: Connect)
We are embarking on a new Industrial Revolution and surely Ethernity will benefit enormously with its products and technology.
Blessed are the patient investors!

100000 buy shown now...I got them at 16.44p early on

Obviously there is little liquidity in the share with management/Institutions and staff/insiders ( and the guys and girls on LSE) holding nearly 85% of the shares in issue.
With a market cap of just c £7m it is the ultimate AIM minnow but if the deals flow the SP could go to amazing highs.
Dyor

MMs playing games trying to draw out a few more sellers....they still haven't reported my buy of 100000 which is over an hour ago.

hi Bid
Nearly there now ...I didn't get anymore at the placing as I wanted confirmation that the company is active and moving ahead.
I got some more..100,000 at 16.6p ish ..early this morning so my holding is very substantial but my breakeven is too high .

I know it is a small contract but it shows the company is still active and has customers who will buy it's products....more to follow imho.
I am more confident now and I am a buyer again.

Tracy
Me again...100000 at 14p
I must be mad but I feel something is afoot dear Watson.

Tracy
To average down from your previous breakeven of 45p
to 20p must have meant you bought nearly 3.5 times your former holding
at 12p
Example 1000 x 45p ..................450
3500 x 12p .................. 420
Therefore now you have 4500 shares costing £ 870 or an average price of 19.3p.
Neither you did not have a lot of shares at 45p or you picked up a very large amount
in the placing or in the market.

For clarification when I said there is no risk here I obviously meant until the trial results are known.

Could stream
Fully agree that the first Phase 3 was a bit of shoe string effort and badly designed with too broad a constituency of Lupus patients many of whom were in remission with their Standard of Care treatments.
Hopefully the new trial will be targeted and clearly defined given the huge mortality risks facing Lupus sufferers from Covid 19 because of their compromised immune systems.
This fact may spur the FDA to fast track the trial process.
From an investment perspective there is no risk here once the FDA agree the new Phase 3 parameters and the share price will move higher imho as the results of the trial get nearer.
As Nolupus said many times in the first trial ...beware of a negative outcome because
you could lose everything and the same advice will stand in a year or so .
Success will lead to amazing gains while failure is too awful to think about.
Derisk on the way is the smart advice for those who intend to take the ride over the next year or
two.
Best to all long suffering investors ( and lupus patients).

My projected 500 trial patients is based on the average cost of $42,000 per patient in a Phase 3 drug trial overseen by the FDA.

An interesting fact......the average cost of a Phase 3 drug trial reviewed by the US FDA over the past 5 years is $20m.
So Avion's $25m is above the average funding and on that basis I predict we will be aiming for c500 patients in the new trial.

Nolupus
The new ( and improved/focussed) Phase 3 trial is all about avoiding the previous trial's mistakes.
No more Mauritius and more emphasis on USA and Europe and on a targeted Lupus population of patients.
$25m is not inconsiderable in terms of a narrow and focussed trial of say 250-300 patients .
The trick will be to find the Lupus patients who are Antibody positive ....via GPs /previous trial patients et al....and then to professionally manage the process. Is Avion up to the task....we better hope so and that the range of experts assisting are of high calibre.
Dr Muller and Hans Zimmer will play a role in Europe but it is all about Avion.
They must have done their homework and are 75% + confident of success because they don't look like a company that afford to chuck $25m down the Swanee on a punt.